Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
Executive Summary
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
You may also be interested in...
IPO Year In Review: Late Rally Gives 50 Newly Public Biopharma Firms A 45.1% Average Return
First-time offerings by drug developers fell from 2018 when 67 launched, but IPO investors’ fortunes improved with a year-end rally providing a 45.1% return versus a 7.5% loss in the prior year.
Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.
US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches
Amgen and Allergan’s launch of the first biosimilars to Roche/Genentech’s Avastin and Herceptin may not face the same commercial dynamics that have stymied biosimilars in other therapeutic areas, but uptake could depend upon oncologists’ comfort level in prescribing the follow-on agents.